首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1634170

全球藥物濫用檢測市場 - 2025 - 2033

Global Drug Abuse Testing Market - 2025 - 2033

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2023年，全球藥物濫用檢測市場規模達72.6億美元，預計2033年將達123.1億美元，2025-2033年預測期間複合年成長率為5.3%。

藥物濫用測試是檢測人體系統中的處方藥、確保安全性、合規性和醫療評估的關鍵過程。它用於工作場所篩檢、法醫調查、體育反興奮劑措施和臨床診斷。它使用尿液、血液、頭髮、唾液或汗水等生物樣本來識別鴉片類藥物、安非他明、大麻素、可卡因和苯二氮平類藥物等物質。藥物濫用日益普遍，增加了藥物檢測對於預防、介入和公共衛生的重要性。

市場動態：

驅動程式和限制

藥物濫用疾病的盛行率上升

由於藥物濫用疾病的盛行率不斷增加，全球藥物濫用檢測市場正在蓬勃發展。政府、醫療機構和雇主正在實施強力的協議來識別和解決成癮問題。未經治療的藥物濫用造成的社會和經濟成本，包括醫療費用、工作場所生產力損失和法律後果，加劇了廣泛檢測的緊迫性。對先進、可靠的藥物檢測技術的需求不斷增加，導致檢測方法的創新和市場的擴大。這凸顯了藥物濫用檢測在緩解全球毒品危機和增強公共衛生方面的關鍵作用。

例如，根據 2023 年美國國家藥物使用與健康調查顯示，12 歲及以上的美國人中有 16.7% 患有物質使用障礙，而 10.2% 患有酒精使用障礙。大約 9.7% 的人患有藥物使用障礙，2.7% 的人兩者都有。此外，7.9% 的成年人在過去一年中同時患有精神健康障礙和藥物濫用障礙或併發疾病。

先進藥品檢測設備成本高

由於先進藥物檢測設備的成本高昂，全球藥物濫用檢測市場面臨挑戰，特別是在低收入地區和規模較小的組織中。 GC-MS 系統和 HPLC 分析儀需要大量的初始投資和持續維護，這使得許多潛在用戶無法負擔。這種財務障礙限制了綜合檢測方法的採用，並透過減少資金不足的醫療機構中可靠的藥物濫用檢測來阻礙市場的成長潛力。

Drug abuse testing is a crucial process for detecting prescription drugs in a person's system, ensuring safety, compliance, and medical evaluation. It is used in workplace screening, forensic investigations, sports anti-doping initiatives, and clinical diagnostics. Using biological samples like urine, blood, hair, saliva, or sweat, it identifies substances like opioids, amphetamines, cannabinoids, cocaine, and benzodiazepines. The increasing prevalence of substance abuse has increased the importance of drug testing for prevention, intervention, and public health.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Substance Abuse Disorders

The global drug abuse testing market is booming due to the increasing prevalence of substance abuse disorders. Governments, healthcare institutions, and employers are implementing robust protocols to identify and address addiction issues. The societal and economic costs of untreated drug abuse, including healthcare expenses, workplace productivity loss, and legal repercussions, have heightened the urgency for widespread testing. The demand for advanced and reliable drug testing technologies has accelerated, leading to innovations in testing methods and expanding the market. This highlights the critical role of drug abuse testing in mitigating the global drug crisis and enhancing public health.

For instance, according to US National Survey on Drug Use and Health 2023 revealed that 16.7% of Americans aged 12 and older had a substance use disorder, while 10.2% had an alcohol use disorder. About 9.7% had a drug use disorder, and 2.7% had both. Additionally, 7.9% of adults had both a mental health disorder and a substance use disorder or co-occurring disorders in the past year.

High Cost of Advanced Drug Testing Equipment

The global drug abuse testing market faces challenges due to the high cost of advanced drug testing equipment, particularly in low-income regions and smaller organizations. GC-MS systems and HPLC analyzers require substantial initial investments and ongoing maintenance, making them less affordable for many potential users. This financial barrier restricts the adoption of comprehensive testing methods and hampers the market's growth potential by reducing reliable drug abuse testing in underfunded healthcare settings.

Segment Analysis

The global drug abuse testing market is segmented based on product type, sample type, end user and region.

Product Type:

Consumables segment is expected to dominate the Drug Abuse Testing market share

The consumables segment holds a major portion of the drug abuse testing market share and is expected to continue to hold a significant portion of the drug abuse testing market share during the forecast period.

Consumables are essential in the global drug abuse testing market, ensuring efficient execution of drug testing procedures. They include test kits, reagents, and sample collection devices, used in various settings like hospitals, clinics, laboratories, workplaces, and at-homes. The high demand for consumables is driven by their recurring use in drug testing and continuous innovation in test kits. As drug abuse testing becomes more widespread, consumption of these essential products increases, making consumables a significant revenue generator. Their role in enhancing efficiency, accuracy, and convenience of drug testing solidifies their importance in the global market.

For instance, in June 2024, FUJIFILM Wako Pure Chemicals Corporation has launched two new tests: LumiMAT Pyrogen Detection Kit (LumiMAT), a next-generation monocyte activation test for in vitro2 pyrogen testing, and PYROSTAR Neo+, a recombinant protein reagent for detecting bacterial endotoxins.

End User:

Hospitals segment is the fastest-growing segment in Drug Abuse Testing market share

The hospitals segment is the fastest-growing segment in the drug abuse testing market share and is expected to hold the market share over the forecast period.

Hospitals are key players in the global drug abuse testing market, providing comprehensive drug testing and treatment. Equipped with advanced diagnostic technologies and trained professionals, they conduct a wide range of tests, from initial screenings to confirmatory tests. They also offer medical interventions for substance abuse issues, including counseling, detoxification, and long-term treatment plans. Hospitals' ability to handle complex cases ensures reliable, accurate, and timely drug testing. Their widespread reach and medical expertise expand the adoption of drug abuse testing in clinical and emergency settings. Hospitals often collaborate with public health organizations, law enforcement, and employers to implement large-scale testing programs, driving demand for drug testing services and consumables.

Geographical Analysis

North America is expected to hold a significant position in the Drug Abuse Testing market share

North America holds a substantial position in the drug abuse testing market and is expected to hold most of the market share due to rising awareness of health risks linked to drug abuse and the need for testing in healthcare, workplace, and law enforcement sectors. The prevalence of substance abuse disorders and high adoption of drug testing technologies in hospitals, clinics, and laboratories contribute to market growth. North America's advanced healthcare infrastructure and well-established systems make it a key player in the market, with significant investments in research, development, and innovation of drug testing products and services.

For instance, in August 2024, Psychemedics Corporation, a global leader in hair testing, has launched a new ketamine hair testing solution, a significant advancement in drug-free workplace detection and prevention.

Moreover, in December 2023, Quest Diagnostics has launched a confirmatory testing service for novel psychoactive substances (NPS), covering 88 compounds across various drug classes. The panel aims to help healthcare providers detect potential drug misuse in patients prescribed controlled medications, such as opioids, amid the proliferation of synthetic or "designer" drugs in the US drug supply. Two of these classes, xylazine and acetyl fentanyl, are accelerating America's overdose crisis.

Europe is growing at the fastest pace in the Drug Abuse Testing market

Europe holds the fastest pace in the drug abuse testing market and is expected to hold most of the market share due to the government initiatives, stricter regulations, and a rise in drug treatment programs. The region's strong healthcare infrastructure and public health campaigns contribute to the demand for accurate testing solutions. Additionally, European countries are investing in research to develop more efficient drug testing solutions, further supporting the market's growth. The demand for accurate and reliable testing solutions is fuelled by the region's strong healthcare infrastructure.

For instance, in August 2023, the Office for Life Sciences, UK has allocated USD 6.24 Billion towards the development of new technologies that modernize testing services. Government efforts also include reducing the rates of deaths and overdoses that result from addictive substances, thus increasing the demand for drug testing solutions.

Competitive Landscape

The major global players in the drug abuse testing market include Siemens Healthcare, Abbott, Thermo Fisher Scientific Inc., LifeSign LLC., MP Biomedicals, Premier Biotech, Inc., MEDACX Ltd, Chromsystems Instruments & Chemicals GmbH, AccuBioTech Co.Ltd., Screen Italia Srl, Paramedical s.r.l among others.

Key Developments

In February 2024, Veriteque USA has partnered with OraSure Technologies to distribute SwabTek surface test kits, a single-use, dry reagent test for narcotics and explosives, alongside its oral fluid drug screening products. This partnership expands OraSure's drug testing portfolio and provides comprehensive solutions for businesses, educators, and security professionals.
In October 2023, Kerala police have introduced a rapid drug screening system called the SoToxa Mobile Test System, which uses saliva samples and provides results in five minutes. The system is currently being trialed in Thiruvananthapuram city and may be expanded to other parts of the state.

Emerging Players

The emerging players in the drug abuse testing market include American Screening Corporation, Inc., Confirm BioSciences, Phamatech, Inc and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global drug abuse testing market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Sample Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Sample Type
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Substance Abuse Disorders
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of Advanced Drug Testing Equipment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Consumables*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Reagents
- 6.2.4. Assay Kits
- 6.2.5. Calibrators and Controls
6.3. Equipment
- 6.3.1. Immunoassay Analyzers
- 6.3.2. Chromatography Instruments
- 6.3.3. Breathalyzers
6.4. Rapid Testing Devices
- 6.4.1. Dip Cards
- 6.4.2. Test Strips
- 6.4.3. Cassettes

7. By Sample Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 7.1.2. Market Attractiveness Index, By Sample Type
7.2. Urine*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Blood
- 7.2.4. Saliva
- 7.2.5. Hair
- 7.2.6. Sweat

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Laboratories
8.4. Forensic Labs
8.5. Home Testing

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Siemens Healthcare*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Abbott Laboratories
11.3. Thermo Fisher Scientific Inc
11.4. LifeSign LLC
11.5. MP Biomedicals
11.6. Premier Biotech, Inc
11.7. MEDACX Ltd
11.8. Chromsystems Instruments & Chemicals GmbH
11.9. AccuBioTech Co.Ltd
11.10. Screen Italia Srl

LIST NOT EXHAUSTIVE